Thursday, October 10, 2013

Let The Pink Vaccine Speak For Itself

By Dr. Kathleen T. Ruddy
The first preventive breast cancer vaccine developed by Professor Vincent Tuohy of the Cleveland Clinic has been controversial since Tuohy’s data were published in Nature Medicine in May 2010.  Apparently the vaccine was so controversial, despite its safety and efficacy in animals studies, that all the traditional funding sources refused to support it.  Fortunately, this impasse has passed.  With the announcement from the Cleveland Clinic that funds are now available to bring Tuohy’s vaccine forward into clinical trials to see if the vaccine is safe for use in women, and if safe, effective in treating and preventing breast cancer, the controversy appears to be heating up.  So be it.  I have no problem with controversy, per se.  Everyone is entitled to their opinion.  That’s the American way.  I respect that.  I admire it.  And, to be sure, I exercise it here and elsewhere often enough to be quite sure of its enduring value.
But I think controversy over the vaccine is rather a waste of time, for the question of the potential of this vaccine is not a matter of opinion, as if it were a passage from the Old Testament open to interpretation, but the proper subject of a scientific investigation.  We don’t need a panel of talmudic scholars to render a judgment about the worth of the vaccine:  what we need is a clinical trial.  And now we have the funds for that.  A scientific study that tests the vaccine for safety and efficacy in women is the proper arbiter of its worth, so let’s go with that and allow the vaccine speak for itself.
I, for one, can’t wait to hear what it has to say.

Press Release From The Cleveland Clinic re: The Pink Vaccine

PRESS RELEASE
Contact:
Joe Milicia, 216.312.0591, milicij2@ccf.org Laura Ambro, 216.470.7961, ambrol@ccf.org
CLEVELAND CLINIC INNOVATIONS CREATES SPIN-OFF COMPANY TO DEVELOP A VACCINE FOR PREVENTING BREAST CANCER Shield Biotech will Seek FDA Permission to Determine Whether Vaccination Can Prevent the Development and Recurrence of Breast Cancer
Tuesday, Sept. 17, 2013, Cleveland: Cleveland Clinic Innovations has created a spin-off company to develop a preventive breast cancer vaccine based on research from Cleveland Clinic’s Lerner Research Institute.
The new company, Shield Biotech, will complete preclinical development and seek permission from the FDA to test the vaccine as an investigational new drug in proof-of- concept, first-in-human clinical trials. The trials are expected to start within two years and will take about three years to complete.
“The mission of Shield Biotech will be to translate the scientific research on a breast cancer vaccine, led by Vincent Tuohy, Ph.D., at Cleveland Clinic, into a viable preventive alternative for the patients who may benefit,” said Thomas Graham, MD, Cleveland Clinic’s Chief Innovation Officer. “We believe that the vaccine has the potential to stop the more lethal forms of breast cancer, as well as inhibiting the recurrence of triple-negative breast cancer in women after they have recovered from their initial disease.”
Initially, Shield Biotech will extend the development to the clinical stage in which the vaccine will be tested in two Phase I clinical trials as part of the process to obtain FDA approval. These trials are designed to establish the safety of the vaccine in women and to characterize and optimize the immune response.
Researchers at Cleveland Clinic’s Lerner Research Institute found that a single vaccination could prevent breast tumors from occurring in mice genetically bred to
Corporate Communications
9500 Euclid Ave. / JJN4-01 Cleveland, OH 44195 Phone: 216.444.0141 Fax: 216.445.3040 clevelandclinic.org/newsroomdevelop breast cancer, while also inhibiting the growth of already existing breast tumors. The research was originally published in Nature Medicine in 2010.
Tuohy, the principal investigator on the original vaccine study, and an immunologist in Cleveland Clinic’s Lerner Research Institute, will be Shield Biotech’s chief science officer.
“We have proposed that breast cancer may be effectively controlled by providing healthy cancer-free women with pre-emptive immunity against emerging breast tumors,” said Tuohy. “We propose to provide women with an immune defense or shield that will protect them from developing breast cancer. Our data show that safe and effective immune protection against this disease can be induced by vaccinating against proteins that are no longer expressed in aging breast tissues but are significantly overexpressed in triple-negative breast cancer, the most aggressive and lethal form of this disease. We hope to provide women with a safe, effective and relatively benign alternative to invasive prophylactic mastectomy.”
Triple-negative breast cancer has a higher recurrence rate than other forms of breast cancer and is insensitive to current forms of adjuvant therapy. It’s the predominant form of breast cancer that occurs, for example, in women with BRCA1 mutations.
G. Thomas Budd, M.D., of Cleveland Clinic’s Taussig Cancer Institute, will be on the company’s scientific advisory board charged with the design and execution of the clinical trial protocol.
The first (Phase Ia) trial will involve women with triple-negative breast cancer who have recovered from current standard of care involving chemotherapy, radiation therapy, and/or surgery. This trial will determine the dose and frequency of vaccination needed to provide an optimum immune response. The second (Phase Ib) trial will involve healthy cancer-free women at high risk for developing breast cancer who have decided to undergo voluntary bilateral mastectomy to lower their risk. This trial will focus on the safety of the vaccine by examining the removed breast tissue for any potential changes.
“We expect these clinical trials to lead to more advanced trials designed to determine the effectiveness of the vaccine in treating triple-negative breast cancer, as well as its potential for immunoprevention,” said Dr. Budd.
For more information, visit http://www.clevelandclinic.org/pinkvaccine
About Cleveland Clinic Innovations
Cleveland Clinic Innovations is responsible for company creation, business development and commercialization of all medical technology throughout Cleveland Clinic and its Innovation Alliance partners which include hospitals and universities throughout the United States and i360 Medical, based in Dublin, and representing the Alliances in many parts of Europe. Since it was founded in 2000, Cleveland Clinic Innovations has filed over 1,600 patents, has more than 400 active licenses and has 63 spin-off companies that
have received nearly $700 million in equity investment. Nearly 1,000 jobs have been generated as a result of Cleveland Clinic Innovations and its spin-offs, having a significant impact on the economic growth in Northeast Ohio.
About Cleveland Clinic
Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States. U.S.News & World Report consistently names Cleveland Clinic as one of the nation’s best hospitals in its annual “America’s Best Hospitals” survey. More than 3,000 full-time salaried physicians and researchers and 11,000 nurses represent 120 medical specialties and subspecialties. The Cleveland Clinic health system includes a main campus near downtown Cleveland, more than 75 Northern Ohio outpatient locations, including 16 full-service Family Health Centers, Cleveland Clinic Florida, the Lou Ruvo Center for Brain Health in Las Vegas, Cleveland Clinic Canada, and, currently under construction, Cleveland Clinic Abu Dhabi. In 2012, there were 5.1 million outpatient visits throughout the Cleveland Clinic health system and 157,000 hospital admissions. Patients came for treatment from every state and from more than 130 countries. Visit us at www.clevelandclinic.org. Follow us at www.twitter.com/ClevelandClinic.

The Pink Vaccine Sets Sail: No Longer “a painted ship upon a painted ocean”

The Cleveland Clinic announced today that it has secured the necessary funds to move the preventive breast cancer vaccine developed by Professor Vincent Tuohy in 2010 forward into a Phase I clinical trial to see if it’s safe for use in women.
As an early supporter of this, the world’s first preventive breast cancer vaccine, I am thrilled that the money that has been denied by traditional funding sources to Professor Tuohy for the last three years has finally materialized.  A scripture reading taken from Psalms – part of my church service this past Sunday – seems appropriate:  ”Thou shalt make me hear of joy and gladness:  that the bones which thou has broken may rejoice.”  And they do.
Tuohy’s vaccine, which took ten years to develop and two years of vetting before his data were published in Nature Medicine (May 2010), is completely safe and 100% effective in preventing breast cancer in three animal models.  The vaccine, which targets an unique protein made in the majority of breast tumors, alpha lactalbumin, is especially powerful against the deadliest form of breast cancer, triple-negative breast cancer.  Triple-negative breast cancer also happens to be the most common tumor found in women who carry a BRCA mutation.  Thus, while Tuohy’s vaccine holds great promise for all women, it is especially promising for women with BRCA mutations and those with triple-negative tumors.
But we must not get ahead of ourselves in rejoicing, for the next step is to test Tuohy’s vaccine in a small group of healthy volunteers to make sure it is safe for use in women.  Such a clinical trial is called a Phase I study, and it must – and will be – rigorously conducted and reviewed.  As happy as we are that the funds required for such a study are now at hand, we must be sober about what lies ahead, for it is a most difficult process to seek permission from the FDA to conduct a Phase I study.  The Cleveland Clinic is ready for the ordeal, and we must be too.
The vaccine must be proved safe.  If it’s not safe, it will be abandoned and rightly so.  But, optimistically, we can say that the vaccine is completely safe in three animal models and, thus, it is reasonable to move forward to see if it’s safe for use in women.
At this juncture there is a cautionary tale to share:  it is the story of the early years of the AIDS epidemic when promising new treatments for patients with HIV languished at the FDA.  It took a vigorous shaking of the cages at the FDA to move HIV drugs more quickly through the approval process.  The result of this grassroots movement, known as “Act Up”, was the creation of a “fast track” through the FDA to accelerate drug approval so that patients who desperately needed new treatments could get them as quickly as possible.
Tuohy’s vaccine, aka the “Pink Vaccine”, should be fast-tracked too.  There are approximately 3 million women now living with breast cancer in the United States, another ~250,000 new cases will be diagnosed by the end of year, with a total of 1.5 million new cases and 500,000 deaths predicted worldwide.  To put a finer point on this staggering data, a woman is diagnosed with breast cancer somewhere in the world every 20 seconds; another one dies every minute.  I can’t think of a better reason to fast track Tuohy’s vaccine than the argument made by this awful arithmetic.
Please help us fast-track the application for a Phase I study of Tuohy’s vaccine through the FDA so that the study can begin as soon as possible.  Millions of lives, millions of breasts, and billions of dollars are at stake in answering the question, Is Tuohy’s vaccine safe for use in women?
“Act Up” taught us to speak up, so speak up and let your Congressmen know that you want Tuohy’s vaccine fast-tracked through the FDA.
Fast-track the Pink Vaccine and “let slip the dogs of war” to prevent this disease.

Complexity Maximus: How to Nail A Breast Cancer Virus

By Dr. Kathleen T. Ruddy
Proving that a virus causes cancer in humans is a woefully convoluted process, guaranteed to drive the sane mad.  To propose, as does the National Breast Cancer Coalition, that simply by deploying $200,000 to what is essentially a mine-sweeping operation to look for evidence of viral DNA in human breast tumors, and that finding viral DNA will be proof sufficient of causation, is misleading, or more precisely, delusional.  Let me explain.
In the beginning, there was ignorance.  No one had any idea what caused cancer.  Thousands of years went by, and still no one had a clue.  A few hundred years ago, it was observed that chimney sweeps (usually young boys who were small enough to slide up and down the chimneys) had a very high incidence of cancer of the scrotum compared to the rest of the men in the population.  Cancer of the scrotum has nothing to do with a virus, but this early observation was the first historical clue that something – in this case, soot – was causally related to a specific cancer.
At the beginning of the 20th century, Peyton Rous (working at the Rockefeller Institute in New York City) discovered that if he injected cell-free fluid taken from a tumor arising in the muscle of a chicken into the leg of a perfectly normal chicken, a fresh and equally malignant tumor would soon grow.  Rous knew then that there must be a virus in that tumor, a virus capable of infecting another animal and producing a similar tumor.  Indeed, Rous had discovered the first cancer virus, now called Rous sarcoma virus, and he couldn’t even see it!  Microscopes were too weak then to see anything smaller than a bacteria.  It would be 30 years before anyone had a microscope powerful enough to see Rous’s sarcoma virus.  Nevertheless, like a faithful Christian, Rous believed he had fingered the first cancer virus.  And he had.
Exactly no one believed him.  A few years later, maybe two or three scientists peaked out from behind a thick black curtain and wondered, What if it’s true?  But everyone else thought he had lost his mind.  They were not the least bit interested in his data, for his idea seemed so absurd that who cared what his data looked like?  The vast majority of his scientific colleagues believed he was just plain wrong, and probably feeble-minded too.  In fact, during a meeting of the first version of the American Cancer Society, it was proclaimed in no uncertain terms that there was no such thing as a tumor virus.  Fair warning to all who dared to cross that line.
Why was there so much skepticism, nay, frank hostility to the idea that a virus (or any infectious agent) might play a role in the formation of cancer?  That’s pretty easy to answer.  You see, cancers arise slowly and tend to grow slowly, while the majority of infectious diseases tend to come on rapidly and are usually quite readily traceable from one sick person to another.  Right?  One person has a cold, goes to work, and three days later, four others at work come down with a cold.  Think of how fast the flu spreads, or small pox, or chicken pox, etc.  But cancer?  Does cancer ever look like it spreads through a population like the measles?  No.  So the idea that cancer might be caused by a virus seemed bizarre.  It didn’t fit with clinical observations and known mechanisms of disease causation or spread.
And then there is the problem of finding the suspected cancer virus in the tumor.  It can be very hard to do.  Sometimes a cancer virus does its dirty work and flees the scene of the crime.  The pathologist peers down the microscope at a sample of tumor and sees no viruses anywhere in the vicinity.  This also makes it hard to prove that a virus causes cancer.
But things get even trickier when there is a suspicion that a virus which is very common in the population, like the herpes virus, is thought to cause cancer.  If a virus as ubiquitous as the herpes virus infects just about everyone in the population at some point in time, but only a few people ever develop the cancer thought to be related to that herpes virus, well you’ve got a job proving the causal link between the two.  Why would only some people get cancer when everyone is infected?  Again, explaining these discrepancies is a chore and a burden for the scientist who wants to argue that virus A causes cancer B.
To make matters flat out confusing, there is the added knowledge that other co-factors may influence the propensity of a virus to cause cancer.   For decades after scientists began to believe that perhaps there might be such a thing as a cancer virus, there was still the problem of identifying other agents, chemicals, and co-carcinogens that might play a role in amplifying the cancer-causing action of a virus.  For instance, it took about two decades to discover that the virus that causes breast cancer in mice requires the presence of estrogen to really get going.  Both male and female mice are equally and as readily infected with the breast cancer virus, but only the females get breast cancer.  Why?  Because the breast cancer virus possesses a segment of its genetic material that is sensitive to estrogen and grows in its presence.  Without estrogen to stimulate it, the mouse breast cancer virus remains dormant.
And, finally, there is the problem that some viruses may enter the cell, appear to be innocent bystanders, and yet trigger distant mutations in the DNA – they’re just in the neighborhood minding their own business, but as capable of transforming a normal cell into a malignancy as any virus that comes into the cell with oncogenes blasting, like the human papilloma virus.
O.K., so now you know how hard it is to find a tumor virus, nail it as a cancer suspect, and prove to scientific colleagues that what you’ve handcuffed in your laboratory is a real McCoy cancer virus.  And, yet, despite the difficulty we are now certain that six viruses cause cancer in humans.  There are surely more:  scientists believe that at least 20% of all human cancers are caused by tumor viruses.  Well then, how do scientists prove that a virus causes a cancer in humans?  After all, you certainly can’t take a putative tumor virus and conduct a randomized clinical trial in which you infect half the volunteers with the cancer virus and give the other half a placebo and then follow the group to see who gets cancer and who does not.  So, if they cannot do it directly, how do scientists prove that a virus causes cancer in humans.
In 1982, as research into tumor viruses became its own branch on the Tree of Knowledge, eight criteria were put forth for proving that a virus causes cancer in humans.  They are:
1.  Patients with the cancer have a higher incidence of antibodies to the virus than healthy subjects.
2.  Antibodies to the cancer virus are higher in cancer patients than in healthy subjects.
3.  The presence of antibodies to the virus precedes the onset of the cancer.
4.  The virus is found only in the tumor and not in normal surrounding tissue.
5.  In the laboratory, the virus is shown to transform normal, healthy cells into malignant tumors.
6.  In the laboratory, the virus produces tumors in animals.
7.  Scientists can detect DNA of the tumor virus in tumors grown in laboratory animals.
8.  Preventing infection by the tumor virus, such as with a vaccine, prevents the malignancy.
Let’s refer to #8 immediately.  The vaccine against the human papilloma virus now used to prevent cervical cancer is an example of the final step required to prove that a virus causes cancer in humans.
As regards the human breast cancer virus, found by Dr. Beatriz Pogo in ~40% of human breast cancer specimens she examined in 1995, the slow journey toward final proof continues.  Of the eight criteria that must be met to prove that a virus causes cancer in humans, six have been met with regard to the human mammary tumor virus.
There are only two steps left to obtain final proof:  #3 and #8.  Actually, as soon as #3 is fulfilled – that is, demonstrating that infection (as documented by the presence of viral antibodies in the bloodstream of volunteers) precedes onset of cancer and increases the risk for it – is the next big thing to do.  Once that is done, a vaccine against the virus can be made and used to fulfill #8 – showing that vaccination against the virus prevents breast cancer.
This is a long blog to say it’s a long slog getting from the question of a breast cancer virus to a vaccine that prevents it.  But, indeed, we are getting close.  And there’s no need to start over from the beginning, as some would suggest we do.  Let’s go from where we are, hovering over #3:  develop a reliable blood test to document infection with the breast cancer virus and then follow a group of healthy volunteers to see who develops antibodies to the virus – a sure sign of infection – and who does not.  And then ask the question, Does becoming infected with this tumor virus precede the onset of breast cancer and increase the risk for it?
Given that there is converging data that suggest 40-75% of all human breast cancer may be related to the same virus that unequivocally causes breast cancer in mice, I suggest we should devote that portion of our breast cancer research dollars trying to nail this murder suspect:  convict or acquit, but don’t ignore.

“Once more unto the breach, dear friends, once more;”

By Dr. Kathleen T. Ruddy
As a new member of the Clinton Global Initiative (CGI), I look forward to actively participating in its annual meeting in New York City, September 22-26.  In fact, I will be hosting a special meeting facilitated by CGI at which Professor Vincent Tuohy of the Cleveland Clinic will discuss his work on the first preventive breast cancer vaccine.  I’d like to share with my readers here the personal statement I’ve posted to my CGI profile, which appears on CGI Connect, a website generated for the 1200+ members expected to arrive in Manhattan next week.  My personal statement represents my vision and my mission to CGI and the world.






My mother was diagnosed with breast cancer in 1974, the same year as Betty Ford. I was a secretary at the time but was thereafter drawn to a career in medicine, first as a physician assistant and then as a surgeon. In 1994, I was chosen as the first Fellow on the Breast Service at Memorial Sloan-Kettering, and in 1995 I was recruited by Cancer Treatment Centers of America to create a Breast Service for the Clara Maass Medical Center in Belleville, New Jersey. My practice grew exponentially; within six months I had 700 patients under my care.
In 2006, I enrolled in the first International Masters for Health Leadership (IMHL) at McGill University. My studies during the IMHL took me first to Kuwait, where I worked with a member of the royal family (Dr. Salman Al Sabah) to create a Breast Service for the Royal Hayat Hospital for Women in Kuwait city. I then received a grant from the WHO to begin a mammogram screening program for women in Uganda. It was during my travels that I first learned of the existence of a human breast cancer virus, and of a very strange, aggressive form of breast cancer ravaging young women in the Gulf and North African countries. I speculated then that if breast cancer was, indeed, related to a virus that the female soldiers deployed to this region during the Gulf Wars would come home with an increased risk of breast cancer.
Such is now the case.
I learned two years ago – and this is documented in peer-reviewed journals – that female veterans of the wars in Iraq and Afghanistan have a 40% increased risk for breast cancer compared to non-military women or soldiers who’ve not served in this part of the world. To date, no funding has been given to further investigate the reasons why.
In 2008, after caring for more than 6000 patients on the Breast Service at Clara Maass, and after traveling the world with the International Masters for Health Leadership, I became convinced that far more attention needed to be given to understanding the causes of breast cancer and implementing all available knowledge to prevent the disease. To my dismay, I discovered that less than 2% of all the money spent on breast cancer research is devoted to primary prevention of this, the most common malignancy in every country in the world. This skewed allocation of resources, weighted so heavily in favor of diagnosis and treatment, didn’t make sense given that the incidence of breast cancer had doubled since President Nixon officially declared War On Cancer in 1971. And, certainly, early diagnosis via mammogram screening was of no service in Gulf countries where the preponderance of breast cancer occurs in women under 40! It seemed to me that the fevered focus on finding a cure was wholly inadequate to meeting the demands of an epidemic notable for its daunting head start and crushing momentum. Certainly, “finding it early” – cleverly marketed as ‘prevention’ when it is no such thing – is a failed strategy for eradicating this or any disease.
When I completed the IMHL in 2008 and returned to the United States to resume my duties in private practice, I felt pulled in two directions: I wanted to continue to care for women with breast cancer and maximize their chance of survival and good health (and spirits), and I wanted this disease to be over, gone, done, away – like polio is history. I decided then to create the first and only breast cancer foundation devoted exclusively to breast cancer prevention, the Breast Health and Healing Foundation (501c3). I’m glad I did, for I feel that every step that preceded this was designed to take me here.
I am particularly interested in the likely role of the mouse mammary tumor virus in causing a significant portion of human breast cancer (estimated to be involved in 40-75% of cases), and in developing a preventive breast cancer vaccine such as the one created by Professor Vincent Tuohy of the Cleveland Clinic in 2010.
My CGI Commitment to Action, embodies my mission to seek the “Pure Cure” for breast cancer – prevention. We’ve done it for cervical cancer by way of a vaccine. I believe we can do it for breast cancer too. In any case, I intend to try.
“Once more unto the breach, dear friends, once more;” (HENRY THE FIFTH, Act 3, scene 1. Shakespeare)

New Genetic Test Predicts Breast Cancer Recurrence within 10 Years

By Vera Viner
When a woman becomes diagnosed with breast cancer, she may have the fear of death surrounding her for years or even decades. Even when breast cancer is cured, the fear of recurrence strikes a chord in many women. Breast cancer survivors may have overcome the initial diagnosis and treatment, but there are still countless women who have their cancer return.
However, science research has once again brought us good news. A new test has been developed to see which women may have their cancer come back within a 10-year period, according to CBS News.
“We have validated a unique ‘fingerprint’ in the primary tumor of breast cancer patients that can help identify a high or low risk of cancer recurrence,” Dr. Paul Goss, director of the Breast Cancer Research Program at Massachusetts General Hospital Cancer Center, said in a release.
The researchers focused on three ways that are currently being used to anticipate recurrence risk in women with estrogen receptor-positive breast cancers. The three methods include the breast cancer index (BCI), the Oncotype Dx Recurrence Score, and a genetic test used to study the ICH4 gene, which is linked to the disease.
The tests were used to study 665 patients. The researchers compared the test results with the patients’ histories to see if breast cancer recurred within five years and after ten years. Only the BCI method was able to accurately predict the recurrence risk within 10 years. All of the methods, however, were able to distinguish the risk within five years time. The test was able to show that 60 percent of the patients were at very low risk of recurrence while 40 percent were at a significant long-term risk.
“Since the BCI identifies two distinct risk groups, it may provide a much-needed tool in determining those patients who need extended hormonal therapy and those who may be spared its well-known adverse side effects,” study leader Dr. Dennis Sgroi, a cancer researcher and pathologist at MGH, told the news source.

A Primer On The Pink Vaccine

By Dr. Kathleen T. Ruddy

The world’s first preventive breast cancer vaccine was developed by Professor Vincent Tuohy, an immunologist at the Cleveland Clinic, in 2010.  Tuohy tested his vaccine over a period of ten years, finding that it was safe and 100%effective in preventing breast cancer in three animal models.  After vetting Tuohy’s data for more than two years, a panel of experts on the editorial review board of Nature Medicine verified and validated his results and then published his paper in May 2010.  While it’s true that not everything that works in mice works in humans, it can be said with equal conviction that everything that now works in humans first worked in mice.
Tuohy’s vaccine targets a protein called alpha lactalbumin (ALA) that is made by the majority of breast cancer cells, especially those that are triple-negative (i.e., lack estrogen, progesterone, and Her2 receptors).  Of note, triple-negative breast cancers are the most common tumors found in women who carry a BRCA mutation.  Because ALA is normally made only in women who are breastfeeding, and since the majority of breast cancer patients are diagnosed with their disease after menopause, Tuohy’s vaccine holds great promise as primary prevention of breast cancer, the most common malignancy in every country around the world.
The next step in furtherance of Tuohy’s vaccine is to conduct a clinical trial in a small group of healthy volunteers to see if the vaccine is safe.  Such a study would likely involve 40-100 women and would take a very short time to complete.  This is called a Phase I study and requires both funding and permission from the FDA before it can begin.  If Tuohy’s vaccine proves safe at the conclusion of a Phase I study, it can then be tested in a Phase II study to assess its effectiveness in preventing breast cancer.  Again, women who carry a BRCA mutation would be ideal candidates for a Phase II study, as they have the highest risk and rates of breast cancer and, thus, an effective preventive breast cancer vaccine would quickly prove its worth in such a cohort of high-risk women.
It is also worth noting that Tuohy’s vaccine, because it targets cells that produce ALA – the majority of breast cancers, especially those that are triple-negative – also holds some therapeutic potential for use in preventing breast cancer recurrence.  But before the vaccine can be moved from the bench to the bedside, the first and most important step must be completed:  we must answer the question, Is Tuohy’s vaccine safe?  That question can only be answered in the course of a Phase I study.  And since so much depends on getting this question answered – millions of lives, millions of breasts, billions of dollars – it’s worth getting the answer as soon as possible.